Candriam Luxembourg S.C.A. boosted its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 396.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,400 shares of the biotechnology company’s stock after acquiring an additional 273,400 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Heron Therapeutics were worth $10,837,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Amalgamated Bank acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $379,000. NewSquare Capital LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $211,000. Pier 88 Investment Partners LLC acquired a new position in Heron Therapeutics in the 2nd quarter valued at about $451,000. Aperio Group LLC grew its position in Heron Therapeutics by 14.4% in the 2nd quarter. Aperio Group LLC now owns 11,261 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 1,416 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in Heron Therapeutics by 339.1% in the 2nd quarter. Wells Fargo & Company MN now owns 265,847 shares of the biotechnology company’s stock valued at $10,329,000 after acquiring an additional 205,302 shares in the last quarter.
NASDAQ HRTX opened at $27.85 on Friday. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of 7.63 and a beta of 1.45. Heron Therapeutics Inc has a 1-year low of $15.00 and a 1-year high of $42.90.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). The company had revenue of $19.79 million during the quarter, compared to analysts’ expectations of $19.84 million. Heron Therapeutics had a negative net margin of 326.79% and a negative return on equity of 72.23%. The business’s quarterly revenue was up 130.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.77) EPS. Equities research analysts anticipate that Heron Therapeutics Inc will post -2.26 earnings per share for the current year.
HRTX has been the subject of several research reports. ValuEngine downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. Cantor Fitzgerald set a $50.00 target price on Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, September 27th. Stifel Nicolaus initiated coverage on Heron Therapeutics in a research report on Thursday, September 13th. They issued a “buy” rating and a $55.00 target price for the company. BidaskClub downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 22nd. Finally, Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “buy” rating and set a $34.00 target price for the company in a research report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $52.09.
In other news, Director Kevin C. Tang sold 2,695,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Kimberly Manhard sold 6,000 shares of Heron Therapeutics stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at approximately $192,420. The disclosure for this sale can be found here. Insiders sold a total of 2,701,494 shares of company stock valued at $96,553,796 in the last quarter. Company insiders own 16.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/16/heron-therapeutics-inc-hrtx-position-lifted-by-candriam-luxembourg-s-c-a.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Further Reading: What Does Beta Mean In Stock Selection
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.